CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Miquel Bernardo

OPENALEX: A5025453526↗ORCID: 0000-0001-8748-6717↗

Affiliations

Organizations

Centre for Biomedical Network Research on Rare Diseasesauthorship · ES Centro de Investigación Biomédica en Red de Salud Mentalauthorship · ES Consorci Institut D'Investigacions Biomediques August Pi I Sunyerauthorship · ES Hospital Clínic de Barcelonaauthorship · ES Instituto de Salud Carlos IIIauthorship · ES Medical Research Networkauthorship · US Neurosciences Instituteauthorship · US Universidad de Oviedoauthorship · ES Universitat de Barcelonaauthorship · ES Universitat de Valènciaauthorship · ES

Public evidence

13 connected articles

Clusters of social and substance use-related risks are associated with the duration of untreated psychosis.2026 · Europe PMC Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMC The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMC Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open Access The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial.2022 · PubMed Central Open Access Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.

Matched by exact identifiers only. Profile data: ORCID. Last retrieved 23/08/2026.

2021 · PubMed Central Open Access

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.2021 · PubMed Central Open Access

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access

Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History.2016 · PubMed Central Open Access

Miquel Bernardo - Medical Cannabis Research Engine